SHINE 2Europe participates in the XII National Congress of Senology

From 6th to 8th November, Cascais hosted the XII National Congress of Senology under the theme “Precision Medicine in Breast Cancer.” SHINE 2Europe took part in this significant event, represented by its CEO, Carina Dantas, who is also a breast cancer survivor. Carina Dantas contributed to a roundtable discussion focused on “Supportive care and improving the quality of life for breast cancer survivors: personalised follow-up.” Her intervention, titled “How to integrate survivors’ needs: the importance of humanising care,” highlighted the central role of empathy and inclusivity in oncology care.

In her presentation, Carina emphasised SHINE 2Europe’s multi-faceted contributions to cancer-related initiatives. SHINE plays an essential role in the Horizon Europe project RadioVal, where it leads the Work Package on Multi-Stakeholder Engagement and Social Innovation. This project focuses on using radiomics artificial intelligence for personalised breast cancer treatment planning.

Carina also spoke about her work as a co-researcher in the Horizon Europe initiative EUonQoL, which aims to develop a European toolkit for assessing the quality of life in oncology. The project involves 27 partners from 32 countries, including health professionals, policymakers, and patient representatives. With validation planned in 45 cancer centres and a release in 27 European languages, the initiative seeks to measure what truly matters to cancer patients and survivors.

SHINE’s CEO drew attention to SHINE’s leadership in various other initiatives, such as chairing the Citizen Engagement Working Group of the Mission Cancer Cluster and contributing to the development of AI-based tools and personalised cancer prevention strategies within Horizon Europe projects.

During the roundtable, Carina highlighted the importance of involving survivors in shaping patient-centred care. Drawing from her personal journey, she stressed the need for systems to humanise follow-up care, ensuring it addresses the comprehensive needs of survivors.

She also presented RadioVal’s innovative approach to improving the outcomes of neoadjuvant chemotherapy. By predicting pathologic complete response (pCR), the project enhances surgical outcomes and optimises treatment plans through AI-driven tools. SHINE’s work in this project ensures that RadioVal fosters collaboration among diverse stakeholders, including patients, AI developers, ethicists, and healthcare professionals, making it both technologically advanced and ethically grounded.

The participation of SHINE 2Europe and Carina Dantas at the XII National Congress of Senology reinforced the organisation’s commitment to leveraging social innovation and public engagement in the fight against cancer. By prioritising inclusivity and quality of life, SHINE continues to push the boundaries of healthcare innovation and advocacy.

Scroll to Top